Search

Search Constraints

You searched for: Author/Creator Safi, Jorge

Search Results

1. 260 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis. (12th April 2019)

2. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. (12th April 2019)

3. Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. Issue 5 (30th April 2020)

4. Inhibition of IL‐17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Issue 8 (25th August 2017)

5. P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses. (26th April 2021)